Kazia Therapeutics(KZIA)
0.3462 0.0020 0.5811%
| 今开：0.3448 | 昨收：0.3442 |
| 最高：0.37 | 最低：0.3301 |
| 涨停价：0.0 | 跌停价：0.0 |
| 总市值：9126367.0 |
Kazia Therapeutics的热门讨论
财报披露
Kazia Therapeutics(KZIA)2021-06-24 18:15
$Kazia Therapeutics(KZIA)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-21-197871 Act: 34 Size: 56 KB 网页链接查看全文
Kazia Therapeutics(KZIA)2020-02-25 19:30
$Kazia Therapeutics(KZIA)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-20-047136 Act: 34 Size: 384 KB 网页链接查看全文
Kazia Therapeutics(KZIA)2020-02-24 19:20
$Kazia Therapeutics(KZIA)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-20-045419 Act: 34 Size: 63 KB 网页链接查看全文
Kazia Therapeutics(KZIA)2020-04-07 18:55
$Kazia Therapeutics(KZIA)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-20-099846 Act: 34 Size: 78 KB 网页链接查看全文
Kazia Therapeutics(KZIA)2020-03-07 06:30
$Kazia Therapeutics(KZIA)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-20-065252 Act: 34 Size: 30 KB 网页链接查看全文
Kazia Therapeutics(KZIA)2021-04-28 18:18
$Kazia Therapeutics(KZIA)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-21-135250 Act: 34 Size: 89 KB 网页链接查看全文
Kazia Therapeutics(KZIA)2021-04-19 18:21
$Kazia Therapeutics(KZIA)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-21-120298 Act: 34 Size: 87 KB 网页链接查看全文
Kazia Therapeutics的最新讨论
产业链观察2023-07-06 19:57
#药闻简讯# $Kazia Therapeutics(KZIA)$ Paxalisib被授予快速通道指定，用于治疗携带PI3K通路突变的实体瘤脑转移瘤，并与放疗相结合查看全文
![[为什么]](http://js.xueqiu.com/ugc/images/face/emoji_14_doubt.png?v=1 "[为什么]"){kind=small}
。![[满仓]](http://js.xueqiu.com/ugc/images/face/emoji_43_add.png?v=1 "[满仓]"){kind=small}
![[俏皮]](http://js.xueqiu.com/ugc/images/face/emoji_04_cool.png?v=1 "[俏皮]"){kind=small}
Kazia Therapeutics的新闻
先声药业(02096)：“SIM0395(Paxalisib)”获国家药监局签发药物临床试验批准通知书
智通财经APP讯，先声药业(02096)发布公告，该公司与Kazia Therapeutics Limited(Kazia)合作的创新药SIM0395(Paxalisib)于2021年12月6日获得中国国家药品监督管理局签发的药物临床试验批准通知书，拟用于胶质母细胞瘤(GBM)，包括新诊断和... 网页链接
Kazia Therapeutics的公告
招股说明书
$Kazia Therapeutics(KZIA)$ 424B3 Prospectus [Rule 424(b)(3)] Accession Number: 0001193125-24-078293 Act: 33 Size: 403 KB 网页链接
财报披露
$Kazia Therapeutics(KZIA)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-24-078281 Act: 34 Size: 4 MB 网页链接
财报披露
$Kazia Therapeutics(KZIA)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-24-077110 Act: 34 Size: 27 KB 网页链接
招股说明书
$Kazia Therapeutics(KZIA)$ 424B3 Prospectus [Rule 424(b)(3)] Accession Number: 0001193125-24-041479 Act: 33 Size: 122 KB 网页链接
财报披露
$Kazia Therapeutics(KZIA)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-24-040846 Act: 34 Size: 23 KB 网页链接
超过5%股东持股披露
$Kazia Therapeutics(KZIA)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001172661-24-001372 Act: 34 Size: 90 KB 网页链接
超过5%股东持股披露
$Kazia Therapeutics(KZIA)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001256071-24-000003 Act: 34 Size: 3 KB 网页链接
生效批准
$Kazia Therapeutics(KZIA)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-24-000320 Act: 33 Size: 1 KB 网页链接
招股说明书
$Kazia Therapeutics(KZIA)$ 424B3 Prospectus [Rule 424(b)(3)] Accession Number: 0001193125-24-024084 Act: 33 Size: 396 KB 网页链接
招股说明书
$Kazia Therapeutics(KZIA)$ F-1 Registration statement for certain foreign private issuers Accession Number: 0001193125-24-019734 Act: 33 Size: 1 MB 网页链接